# CapsoVision Inc. (CV) fundamentals

Data as of 2026-09-09. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $6.36, market value $318 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). CapsoVision Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 22.9×**. Each dollar of revenue is priced at 22.9×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 24.2×**. The shares trade at 24.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -8.8%** (5-yr avg -8.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 50.9%**. CapsoVision Inc. keeps 50.9% of revenue after the direct cost of what it sells.
- **Operating margin: -217.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -186.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -190.9%**. Return on equity is negative because earnings are negative.
- **Return on assets: -164.2%**. Each dollar of assets produces -164.2% of profit.

## Growth
- **Revenue growth (1 yr): 15.3%**. Revenue grew 15.3% over the last year.
- **EPS growth (1 yr): 89.5%**. Earnings per share rose 89.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 3.77** (quick 3.77). Current assets cover the next year's liabilities 3.77 times.
- **Altman Z-score: 34.62**. A Z-score of 34.62 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. CapsoVision Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (2 analysts). 2 analysts cover CapsoVision Inc.; the consensus is strong_buy, with an average price target of $9.50 (+49% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 58.5%** (YTD -44.0%, 3-mo -16.7%). The shares are up 58.5% over twelve months including dividends.
- **From 52-week high: -58.6%** (81.7% above the low). Trading 59% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 0.92** (volatility 98%). Beta of 0.92 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CV · Page: https://foliofundamentals.com/stocks/cv

Not investment advice.